---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-22-005036"
form_type: "8-K"
ticker: "PMCB"
cik: "0001157075"
company_name: "PharmaCyte Biotech, Inc."
filed_at: "2022-07-19T23:59:59+00:00"
generated_at: "2026-06-24T12:03:04.448316+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# PharmaCyte reports positive interim results in malignant ascites mouse model study

## Summary
- Study conducted by Heidelberg Pharma using colon carcinoma cells from Austrianova Master Cell Bank in mice.
- Initial data indicates overall tumor volume (Sugarbaker-index) more accurate than fluorescence for tumor burden.
- Objectives include optimizing tumor cell dose, timing curve, and assessment method.
- CEO Kenneth Waggoner says study proceeding as hoped; confident all objectives will be achieved.
- Malignant ascites has no approved treatment; therapy aims to slow or eliminate fluid accumulation.

## SEC filing metadata
- accession: 0001683168-22-005036
- form_type: 8-K
- ticker: PMCB
- cik: 0001157075
- company_name: PharmaCyte Biotech, Inc.
- filed_at: 2022-07-19T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1157075/000168316822005036/0001683168-22-005036-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1157075/000168316822005036/pharmacyte_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-22-005036
- JSON: https://secwatch.observer/filing/0001683168-22-005036.json
- Plain text: https://secwatch.observer/filing/0001683168-22-005036.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.